Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ascites Clear all
Recruiting Phase 2 Interventional

Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites

NCT06812390
View directory record Official record
Conditions
Cirrhosis, Ascites Hepatic
Interventions
Albumin infusion (25% albumin), Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Anahita Rabiee MD MHS
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Phase 3 Interventional

Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver

NCT00366795
View directory record Official record
Conditions
Ascites, Liver Cirrhosis
Interventions
Satavaptan, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Malvern, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Jul 21, 2026, 2:19 PM EDT
Completed No phase listed Observational

Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women

NCT00552955
View directory record Official record
Conditions
Lymphangioleiomyomas, Tuberous Sclerosis, Lymphangioleiomyomatosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Jul 21, 2026, 2:19 PM EDT
Recruiting No phase listed Observational

QOL and Sarcopenia in Patients With Ascites

NCT05726747
View directory record Official record
Conditions
Ascites Hepatic, Ascites, Malignant
Interventions
Quality of Life surveys
Diagnostic Test
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Completed No phase listed Observational

International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project

NCT05387811
View directory record Official record
Conditions
Liver Cirrhosis, Acute Kidney Injury, Hepatorenal Syndrome
Interventions
Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy
Combination Product
Lead sponsor
Azienda Ospedaliera di Padova
Other
Eligibility
18 Years and older
Enrollment
1,456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Jul 21, 2026, 2:19 PM EDT
Recruiting Phase 1 Interventional

Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics

NCT05490888
View directory record Official record
Conditions
Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic
Interventions
PHIN-214 Subcutaneous injection
Drug
Lead sponsor
PharmaIN
Industry
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Chandler, Arizona • Coronado, California • Marrero, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jul 21, 2026, 2:19 PM EDT
Withdrawn Not applicable Interventional

HepQuant to Predict Hepatic Encephalopathy After TIPS

NCT04664621
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Liver
Interventions
HepQuant
Diagnostic Test
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional

Tackling 30-day Readmissions in Patients With Cirrhosis: The SALTYFOOD Trial

NCT03493204
View directory record Official record
Conditions
Hepatic Encephalopathy, Ascites, Liver Diseases, Cirrhosis
Interventions
Meal delivery, Standard pamphlet with Dietary Advice
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional

Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stents

NCT04315571
View directory record Official record
Conditions
Hypertension, Portal, Ascites
Interventions
Gore® Viatorr® Endoprosthesis with controlled expansion, Large Volume Paracentesis with albumin infusion
Device · Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional Results available

Improving Performance of Paracentesis in Medical Residency Training

NCT01403987
View directory record Official record
Conditions
Ascites, Cirrhosis
Interventions
Residency Program Teaching, Lecture, Pocket Card Reference, Pager
Behavioral · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
Not listed
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Jul 21, 2026, 2:19 PM EDT
Completed No phase listed Observational

Long-term Follow-up of HALT-C Sustained Virological Responders

NCT00825877
View directory record Official record
Conditions
Hepatitis C, Hepatocellular Carcinoma, Ascites, Variceal Hemorrhage, Death
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 21, 2026, 2:19 PM EDT
Recruiting Phase 2 Interventional

Empagliflozin in Patients With Cirrhosis and Ascites

NCT05726032
View directory record Official record
Conditions
Cirrhosis, Liver Failure
Interventions
Empagliflozin 10 MG, Matching Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional

A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury

NCT05309200
View directory record Official record
Conditions
Cirrhosis, Ascites, Hepatorenal Syndrome, Acute Kidney Injury
Interventions
OCE-205, Placebo
Drug
Lead sponsor
Ocelot Bio, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional

Telehealth Intervention in Cirrhotics

NCT03969186
View directory record Official record
Conditions
Cirrhosis, Liver, Liver Diseases
Interventions
Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional

Insertion Technique in Large Volume Paracentesis

NCT02310165
View directory record Official record
Conditions
Cirrhosis
Interventions
Z-tract Insertion Technique, Coaxial Insertion Technique
Procedure
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated No phase listed Observational

Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)

NCT02026609
View directory record Official record
Conditions
Refractory Ascites, Hepatic Hydrothorax, Hepatic Encephalopathy, Cirrhosis
Interventions
Oral glutamine challenge, Psychometric Tests
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Phase 2 Interventional

A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites

NCT04112199
View directory record Official record
Conditions
Ascites, Decompensated Cirrhosis
Interventions
BIV201 continuous infusion
Drug
Lead sponsor
BioVie Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Jacksonville, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional

End Stage Liver Disease and Body Composition Assessment: Utilizing Bioelectric Impedance Analysis (BIA)

NCT00374582
View directory record Official record
Conditions
End Stage Liver Disease
Interventions
Bodystat Quadscan 4000, bodystat quadscan 400
Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2011 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional

Impact of Palliative Catheter Placement on the Quality of Life of Patients With Refractory Ascites

NCT01188746
View directory record Official record
Conditions
Ascites
Interventions
McGill Quality of Life Questionnaire and the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional Results available

The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy.

NCT04675775
View directory record Official record
Conditions
Cirrhosis, Ascites, Liver Diseases, Frailty, Sarcopenia, Hepatic Encephalopathy
Interventions
Medically-tailored meals (MTM), Protein supplements, Nutrition education handout
Other · Dietary Supplement · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02122185
View directory record Official record
Conditions
Brenner Tumor, Malignant Ascites, Malignant Pleural Effusion, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Primary Peritoneal Cavity Cancer
Interventions
metformin hydrochloride, placebo, Chemotherapy
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Mobile, Alabama • Duarte, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Withdrawn No phase listed Observational

Effect of Large Volume Paracentesis on Fatigue in Cirrhosis

NCT00603200
View directory record Official record
Conditions
Ascites, Fatigue, Cirrhosis
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional

Evaluation of Hemodynamic Parameters Following Transjugular Intrahepatic Portosystemic Shunt (TIPS)

NCT04050683
View directory record Official record
Conditions
Refractory Ascites
Interventions
Study - Transjugular Intrahepatic Portosystemic Shunt (TIPS), Control - Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Phase 3 Interventional

Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver

NCT00359437
View directory record Official record
Conditions
Ascites, Liver Cirrhosis
Interventions
Satavaptan, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Malvern, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Jul 21, 2026, 2:19 PM EDT